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Abstract: Phage display is a nanotechnology with limitless potential, first developed in 1985 and
still awaiting to reach its peak. Awarded in 2018 with the Nobel Prize for Chemistry, the method
allows the isolation of high-affinity ligands for diverse substrates, ranging from recombinant
proteins to cells, organs, even whole organisms. Personalized therapeutic approaches, particularly
in oncology, depend on the identification of new, unique, and functional targets that phage display,
through its various declinations, can certainly provide. A fast-evolving branch in cancer research,
immunotherapy is now experiencing a second youth after being overlooked for years; indeed,
many reports support the concept of immunotherapy as the only non-surgical cure for cancer,
at least in some settings. In this review, we describe literature reports on the application of peptide
phage display to cancer immunotherapy. In particular, we discuss three main outcomes of this
procedure: (i) phage display-derived peptides that mimic cancer antigens (mimotopes) and (ii)
antigen-carrying phage particles, both as prophylactic and/or therapeutic vaccines, and (iii) phage
display-derived peptides as small-molecule effectors of immune cell functions. Preclinical studies
demonstrate the efficacy and vast potential of these nanosized tools, and their clinical application is
on the way.
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1. Introduction
The immune system changes and adapts during the progressive steps of tumorigenesis to recruit
and activate all possible mechanisms of protection. The initial response provides a first line of defense
that keeps the neoformation in check. During this phase, the innate immune system recognizes cancer
cell neoantigens (often called tumor-associated antigens (TAAs)) the same way it detects the presence
of foreign organisms, e.g., pathogenic bacteria or viruses. Upon interaction with circulating TAAs,
specific clones of B lymphocytes are amplified to produce high titers of anti-TAA antibodies (Abs).
Antigen-presenting cells (APCs) bind, process, and expose the TAA on the major histocompatibility
complex (MHC). Naïve T lymphocytes are recruited and primed upon interaction of T-cell receptors
(TCRs) and co-receptors (expressed on T lymphocytes) with TAA-MHC complexes and co-ligands
(expressed on APCs), respectively [1,2]. When the TAA is presented on MHC I, the complex is
recognized by CD8+ cells that differentiate in cytotoxic T lymphocytes (CTLs) and kill cancer cells [3]
causing the release of additional TAAs and amplification of the immune response [4]. When the TAA
is loaded on MHC II, CD4+ T lymphocytes are engaged to differentiate in T helper (Th) lymphocytes
that support the functions of B lymphocytes. T-cell co-receptors (the so-called “immune checkpoints”)
can have a stimulatory or inhibitory effect. CD28 was the first co-stimulatory molecule to be identified,
and the interaction between CD28 and B7.1/B7.2 is required for full activation of naïve T lymphocytes.
In contrast, CTL-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1), when interacting
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with their ligands PDL-1/PDL-2 and B7.1/B7.2, respectively, restrain the activation of T lymphocytes
and are thus considered co-inhibitory molecules [5].
While efficiently controlling tumor growth, immune responses also introduce a strong selective
pressure that, with time, impacts on cancer cells, making them able to elude the immune surveillance
and keep growing via genomic instability, anti-apoptotic pathways, angiogenesis, and eventually,
metastatic spreading [6,7]. In addition, self-recognition mechanisms—whose physiological function is
to prevent the immune system from attacking the host—may as well reinforce the escaping potential of
cancer cells. Cancer immunotherapy is based on inducing a person’s immune system to attack tumor
cells [8,9]. It involves a wide variety of therapeutic modalities such as Abs, vaccines, cytokines, and cell
therapies that either stimulate antitumor responses (by activating effector cells) or impair suppressor
mechanisms (by blocking the immune checkpoints). In a nutshell, immunotherapy boosts the innate
power of our organism to combat cancer [10].
Conventional approaches for the therapeutic induction of anti-cancer immune responses follow
three general concepts. First, anti-TAA Abs may be administered to patients, a procedure known
as passive immunization. Since the invention of the hybridoma technology by Kohler and Milstein
in 1975 [11], enormous efforts have been made on the characterization of monoclonal Abs as
tumor-targeting agents. Several Abs have been developed against extracellular, transmembrane,
or intracellular proteins to nullify the pathological mechanisms implemented by tumor cells, many of
which have received Federal Drug Administration (FDA) approval [12–16]. These applications, however,
suffer of some drawbacks that range from engineering human/humanized Abs to the need of repeated
administrations to obtain effective serum levels of the Ab [17]. Ideally, a continuous and endogenous
production of anti-TAA Abs would best serve the aim of achieving a therapeutic effect with the potential
to eradicate the disease and prevent its recurrence for the rest of a patient’s life. This second concept,
known as active vaccination, was historically developed to combat pathogenic organisms but has been
recently pursued also in oncology. In this context, TAAs or TAA-mimicking molecules (mimotopes),
soluble or conjugated to different nanocarriers, have been tested as cancer vaccines [18–22]. Finally,
the third concept is a straightforward approach that has been defined “meddle with meddlers” [23],
as in directly targeting the immune checkpoint inhibitors.
These three concepts have been applied to cancer treatment by means of different tools
(e.g., peptides, Abs, aptamers, chemical molecules) developed with conventional techniques as
discussed elsewhere [24–26]. Here, we focus on peptide phage display, performed with many variations
from the original protocol, often in combination with advanced computational modelling. Phage display
is a high-throughput proteomic method based on viruses that infect bacteria, the bacteriophages
(in short, phages). These viruses vary widely in size (from 28 × 28 nm of phage Qβ to 900 × 7 nm of
phage M13) and shape (icosahedral, with or without tail, filamentous), yet sharing important common
features: they (i) naturally and quickly propagate in their bacterial host and are therefore suitable for
molecular manipulations, (ii) are capable of self-assembly to provide ready-to-use nanosized tools,
(iii) are easily engineered to expose one or more copies of a peptide fused to their capsid proteins.
Starting from a library of millions of unique motifs, successive rounds of affinity selection are applied
to isolate target-specific peptides. From this point on, the applications are manifold. The general uses
and characteristics of phages as peptide-directed vectors for targeted nanomedicine are extensively
discussed in the literature, for example in the comprehensive reviews by Yao [27] and Hess [3] and
colleagues. The aim of the present review is to specifically address the applications of phage display
nanotechnology in the field of immuno-oncology and to provide a broad overview of the different
approaches explored in animal models, and in some cases, also in early-phase clinical trials.
2. Mimotopes of Tumor-Associated Antigens
Due to their specific and often very high expression, TAAs are attractive targets for cancer therapy.
Ways to trigger the production of anti-TAA Abs include administration of either full-length TAAs,
their antigenic parts only, or TAA mimotopes (e.g., anti-idiotype Abs or peptides recognized by the
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anti-TAA Ab). There is a vast literature on phage display panning of either monoclonal or polyclonal
Abs to identify TAA mimotopes, in some cases even without knowledge of the corresponding natural
epitope (see, e.g., [28]).
2.1. Mimotopes of CD20
CD20 is a 33–35-kDa non-glycosylated phosphoprotein expressed on B lymphocytes from the
early pre-B to the late-B stage. Its expression is lost after differentiation of B lymphocytes into plasma
cells, but the majority of human B-lineage malignancies re-express CD20, making it a likely targetable
TAA. Panning the anti-CD20 Ab rituximab with phage-displayed peptide libraries has provided
several mimotopes that could be developed as cancer vaccines. Among these, the linear 12-mer R10-L
(ITPWPHWLERSS), despite having no homology to CD20, was shown to interact with rituximab and
inhibit its binding to CD20. Anti-CD20 Abs were present in sera from BALB/c mice immunized with
R10-L, as confirmed by binding assays on the CD20+ human B-lymphoid cell line Raji [29]. A mimotope
identified in an independent panning, QDKLTQWPKWLE, revealed a 6-aa motif with >80% identity to
R10-L and was shown to inhibit rituximab to Raji cells. This peptide was coupled to keyhole limpet
hemocyanin (KLH) or tetanus toxoid (TT) and evaluated in experimental vaccinations of BALB/c mice.
Sera raised against either QDKLTQWPKWLE-KLH or QDKLTQWPKWLE-TT recognized cell-surface
CD20 and specifically killed Raji cells in complement-dependent cytotoxicity assays [30]. In a successive
work from the same group, alignment of several phage-selected 7- and 12-mers confirmed the same
6-aa motif (WPxWLE) that the authors assigned to a reverse-oriented portion (161WPKWLE156) of acid
sphingomyelinase-like phosphodiesterase 3b (ASMLPD). Corresponding synthetic peptides inhibited
both rituximab binding and rituximab-induced, complement-dependent cytotoxicity in a specific
and dose-dependent manner. Sera from BALB/c mice immunized with WPxWLE peptides reacted
with both Raji cells and the human Burkitt’s lymphoma cell line Daudi (both CD20+) but not with
the human T cell leukemia cell line CEM (CD20-). Further selections with phage-displayed libraries
exposing cyclic 7-mers allowed to identify peptides that share the (A/S)NPS motif mapping to the
extracellular portion of human CD20 (170ANPS173). Sera raised against these peptides were cytotoxic
for Raji and Daudi cells in the presence of complement [31]. A panel of eleven variants, all including the
rituximab-specific antigenic motif but with different flanking residues, were used for epitope mapping.
The panel was narrowed to R13-C (WAANPS, identical to CD20 epitope) and R15-C (PYANPSL,
flanking residues different from the natural epitope), which exhibited similar reactivity to rituximab.
In vivo, R13-C elicited anti-CD20 Abs more consistently than R15-C (5 out of 5 versus 2 out of 5 mice),
demonstrating the contribution of epitope-surrounding residues to Ab specificity [32]. Previously
identified as mapping to ASMLPD, R5-L (WPKWLE) was successively characterized as an antigenic
mimic of raft-associated CD20, mapping to a different epitope from, and showing no cross-inhibition
with R15-C (PYANPSL). Computer modelling of possible contacts between R5-L/R15-C and rituximab
indicated that these two motifs have similar—yet not identical—tertiary interactions with the Ab,
and that they share some contact points within the rituximab/antigen binding site [33]. Abs against
R5-L were produced by hybridoma technology, and clones FE-718 and FE-341 were chosen for further
studies. Both Abs dose-dependently, and to a similar extent, inhibited rituximab binding to R5-L in a
competitive binding assay. However, neither FE-718 nor FE-341 were able to detect cell-surface CD20.
Epitope mapping of these Abs by phage display provided the consensus sequence WPxxL, similar to
R5-L and recognized by sera from R5-L-immunized BALB/c mice. So, these CD20 mimotopes and
their corresponding Abs exhibit both common and divergent features that can be exploited to design
therapeutic tools. Further, these studies demonstrate that a 6-aa peptide motif (much shorter than
the whole extracellular portion of CD20) can induce various immune responses [34] and that phage
display is a powerful nanotechnology to get insight into the molecular basis of epitope spreading.
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2.2. Mimotopes of the Epidermal Growth Factor Receptor
The epidermal growth factor receptor (EGFR, also called HER or ErbB) is a member of the EGFR
family found overexpressed and/or mutated in many solid tumors, e.g., lung, neck, breast, kidney,
and colon. This feature makes EGFR a great target for cancer treatment. Several anti-EGFR Abs have
been developed, among which cetuximab, panitumumab, nimotuzumab, 12H23, Ch806, and ICR-6214.
Although in early-stage clinical studies, prolonged treatment with cetuximab or matuzumab was
generally well-tolerated with skin reactions such as an acne-like rash being the most common side
effect, once phase II was reached, some anti-EGFR Abs showed disappointing results and scheduled
trials were cancelled (matuzumab being one of them). A way to circumvent this drawback is to develop
alternative approaches by exploiting the mimotope strategy. A number of mimotopes recognized
by those Abs have been discovered with the phage display technique and mimotope-based vaccines
have been consequently designed. Four peptide mimics of the epitope recognized by cetuximab were
isolated from a cyclic 10-mer library, although none shared sequence similarities to either EGFR or
other family members. Based on the specific binding to cetuximab, two of them (CQFDLSTRRLKC and
CQYNLSSRALKC) were chosen for in vivo immunization studies after coupling with the immunogenic
carrier KLH. Both mimotopes elicited Abs capable of triggering (i) cellular and complement-dependent
cytotoxic effects against EGFR-expressing cells, (ii) EGFR internalization, and (iii) dose-dependent
inhibition of proliferation in the EGFR-overexpressing human squamous carcinoma cell line A431 [35].
In another work, different phage-displayed peptide libraries (liner 7-mer, linear 12-mer, and cyclic
7-mer) were panned on cetuximab and matuzumab single-chain Fv Ab fragments (scFv) presented
by Escherichia coli cells, with a procedure known as delayed infectivity panning [36]. The peptide
motifs KTL and YPLG were retrieved as antigenic for both cetuximab and matuzumab, despite the
non-overlapping EGFR epitopes previously reported for these Abs. In experimental immunizations of
mice, synthetic KTL- and YPLG-containing peptides elicited Abs that recognize cell-surface EGFR and
compete with natural ligands for receptor binding and activation, with an efficacy similar to cetuximab
and matuzumab. Competition experiments demonstrated that the epitopes recognized by the anti-KTL
and anti-YPLG Abs are close to, or overlap with, the binding sites of cetuximab, matuzumab, or the
natural ligands transforming growth factor α (TGF-α) and EGF [37].
Mimotopes for other anti-EGFR Abs have also been selected, although with debatable results.
Two potential peptide mimics of EGFR (WHTEILKSYPHE and LPAFFVTNQTQD) were identified by
phage display panning of Abs 12H23 and Ch806. Mice immunized with WHTEILKSYPHE-KLH or
LPAFFVTNQTQD-KLH developed high-titer Abs that recognized both EGFR and its variant EGFRvIII
overexpressed on cancer cells. The mimotopes of this study were capable of inducing Ab-dependent
but not complement-dependent cytotoxicity [38]. Another EGFR mimotope (QHYNIVNTQSRV)
was identified by phage selection on Ab IRC-62 and validated by enzyme-linked immunosorbent
assay (ELISA). A synthetic version of this peptide, conjugated to bovine serum albumin (BSA),
was administered to rabbits in a vaccination experiment. The induced Abs bound to purified EGFR and
inhibited the growth of A431 cells while having no effect on the EGFR-negative human melanoma cell
line MDA-MB-453 [39]. In a similar work, epitope mapping of the same Ab, ICR-62, led to the isolation
of a mimotope-displaying phage that was used in vaccination experiments, although with poor results,
i.e., low titers of induced anti-EGFR Abs and neither prophylactic nor therapeutic efficacy in an in vivo
model of Lewis lung carcinoma [40]. Finally, two other mimotopes, P19 (DTDWVRMRDSAR) and
P26 (VPGWSQAFMALA), were selected by panning the anti-EGFR Ab panitumumab. Molecular
modelling showed that, despite no sequence homology with EGFR, both P19 and P26 recapitulate
the conformational structure of EGFR surface binding to panitumumab. Coupled with heat-shock
cognate protein 70 (Hsc70) as an immunogenic carrier, both P19 and P26 stimulated the production
of specific Abs in mice. The conjugates induced both Ab- and complement-dependent cytotoxicity
and inhibited the proliferation of A431 cells. In addition, treatment with Hsc70-P19 and Hsc70-P26
reduced tumor growth in severe combined immunodeficient (SCID) mice bearing xenografts of the
human lung cancer cell line A549 [41].
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2.3. Mimotopes of HER2
HER2 (ErbB-2 or Her-2/neu), the product of the c-erbB-2 protooncogene, is a transmembrane,
ligand-less tyrosine kinase receptor found to be overexpressed in several tumors, among which
ovarian, prostate, and breast, whereas it is rarely expressed in normal adult tissues. Transtuzumab
(Herceptin®), a humanized version of mouse anti-ErbB-2 clone 4D5, is clinically used to treat metastatic
breast tumors that overexpress HER2. However, chimeric or humanized Abs are still recognized as
foreign proteins and can trigger severe side effects due to hypersensitivity reactions, thus requiring a
careful management of treatments. With this premise, a mimotope-based vaccination strategy may
represent an option to elicit endogenous antitumor Abs while inducing a long-lasting immunologic
memory. In an initial study, candidate mimotopes isolated by panning trastuzumab with a cyclic
10-mer phage-displayed library were validated as HER2 mimics in both direct and competitive ELISA.
Immunization of BALB/c mice was performed with one of the selected peptides (CQWMAPQWGPDC)
conjugated to TT, resulting in the production of Abs that recognized HER2 both in Western blot
and on the surface of the HER2+ human breast cancer cell line SK-BR-3. Similar to trastuzumab,
these Abs also induced HER2 internalization [42]. A different approach was applied in a more recent
study, where an adeno-associated virus (AAV) library was panned on trastuzumab to identify HER2
mimotopes. The aim of this work was to obtain a vector suitable for immunization trials without further
modification. Seven candidate peptides of consensus sequence WxxGxAxGS were tested in vivo and
two were classified as optimal candidates based on (i) capacity to induce an Ab response, (ii) specificity
of the induced Abs, and (iii) capacity to inhibit proliferation when applied to HER2-overexpressing
cancer cells. Prophylactic vaccination of mice prior to subcutaneous grafting with HER2+ syngeneic
D2F2/E2 cancer cells resulted in delayed tumor growth [43].
Phage display has also been applied to anti-HER2 Abs L26, N12, and L288. Of the selected
motifs, peptide 52 (ALVRYKDPLFVWGFL), mapping to a portion of HER2 close to the natural epitope,
competed for the binding of HER2 to L26 [44]. In a further study, epitope mapping of the anti-HER2
Ab SER4 provided another potential mimotope (INNEYVESPLYM) that shares homology with the
region 87AHNQVRQVPLQR98 in the extracellular domain of HER2 [45]. However, to our knowledge,
there has been no follow up to these potentially promising studies.
2.4. Miscellaneous Mimotopes
Another line of research that started early in the era of phage display is the search for mimotopes
of prostate membrane specific antigen (PSMA, also called prostate specific antigen, PSA). Three motifs
(VDPGKYNKY, EGPAKGFKL, and GCYEAPSKAAKC) were isolated from panning the anti-PSA Ab
4G5. Sequence analysis demonstrated homology with a liner epitope within the extracellular portion
of PSA (aa 719-725) [46]. In a more recent study, ten clones were isolated from a peptide phage display
screening on a commercial anti-PSA Ab, four of which (RRSHPCRTCTTHTP, HRKTTCTRCPATSP,
HRRGECRACPLLPA, and RRPAHCHHCPRNP) were further characterized. Their immunogenicity
was determined by vaccination of BALB/c mice, with each peptide inducing Abs with minimal
cross-reactivity to each other. In vitro, Abs specific to one peptide were capable of recognizing
full-length PSA by Western blot, further confirming the mimotope properties [47].
In addition to PSA, other tumor markers have been investigated, such as the carcinoembryonic
antigen (CEA), a 180-kDa glycoprotein composed by ~50% carbohydrates and frequently expressed in
adenocarcinomas of various tissues of origin. Two phage-displayed peptide libraries (cyclic 10-mer
and linear 9-mer) were screened on the anti-CEA Ab Col-1. The motif showing the highest specificity
(DRGGLWKTP) was synthesized as an octameric multiple antigenic mimotope (MAM) of formula
(DRGGLWKTP-GG)4-(KKGGC)2-dithioacetylhexandiamin. BALB/c mice immunized with this MAM
mounted a specific anti-CEA humoral response (prevalently IgM and IgG2, with limited amounts of
IgG1 and IgG2a). In vitro, these Abs triggered both Ab- and complement-dependent cytotoxicity against
the CEA+ human colorectal cancer cell line HT29, but not against the CEA- cell line SW480. In vivo,
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immunization with the MAM led to delayed tumor growth in mice challenged with CEA-overexpressing
syngeneic Meth-A fibrosarcoma cells [17].
Finally, phage display has also been applied to identify peptides specific for bevacizumab
(Avastin®), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal Ab approved
for anti-angiogenic treatment of cancer. One of the selected peptide motifs (12P, DHTLYTPYHTHP)
showed selective binding to bevacizumab and was further characterized. A synthetic version of
the peptide was produced and conjugated to KLH to be used as a potential vaccine (KLH-12P).
Mice injected with KLH-12P mounted a substantial humoral response, and sera from immunized mice
inhibited VEGF binding to its receptor, as well as cell proliferation and migration [48].
2.5. Mimotopes of Unknown Antigens
A number of Abs recognizing the surface of gastric cancer cells have been identified,
whose corresponding antigens remain uncharacterized. In this setting, the search for Ab-binding
mimotopes is expected to provide insight into the nature of the TAA itself, in light of perspective clinical
applications. A research group based in China generated a panel of monoclonal Abs against gastric
cancer, designated as MG series. In one study, a phage-displayed 7-mer library was panned on MGb1
Ab providing potential mimotopes with the common motifs HxQ and LxS. A synthetic version of these
peptides showed weak competition (20%) for the binding of MGb1 Ab to the human gastric cancer cell
line KATO III. These results do not appear particularly promising, especially in the absence of in vivo
evidence [49]. In another study from the same group, libraries of phages displaying 9-mer peptides in
linear or cyclic form were used for epitope mapping of MG7 Ab. Phages exposing selected peptides
proved to be specific both in dot blot and ELISA, and convincingly (>70%) competed for binding
to KATO III cells. Immunization of BALB/c mice produced antisera, which, however, failed to react
with gastric cancer cells, except for sera against GC8 (NAIYARNAQ), GC9 (TCHLRVYAQ), and GC28
(SWAPVYARN) [50]. Additional peptides selected by phage display on MG7 Ab were evaluated in two
therapeutic strategies. Firstly, a single MG7 mimotope (KPHVHTK) [51] was associated to adjuvant CpG
oligodeoxynucleotides in nanoemulsion. Immunization with these nanoemulsion induced interferon γ
(IFN-γ) production in splenocytes—as determined by Enzyme-Linked ImmunoSPOT (ELISPOT)—and
triggered a humoral response against MG7 antigen [52]. Secondly, four MG7 mimotopes (the previously
cited KPHVHTK, plus KPHLHFH, KPHSHLH, and SWAPVYARAN) were individually conjugated to
Hsp70 and combined in a multi-epitope vaccine. In vivo, MG7 Ab titers of the multi-epitope vaccine
group were significantly higher than those of the mono-epitope group. Similarly, in mice treated with
the multi-epitope vaccine, Ehlrich ascites carcinoma EAC xenografts were markedly smaller than
tumors in the control animals [53].
Among other cancer-specific Abs whose antigen remains unknown, BCD-F9 is of potential interest
because it is able to reduce the growth and metastasis of the human fibrosarcoma cell line HT-1080 in
animal models. Screening a phage-displayed 10-mer library on this Ab allowed to isolate a peptide
motif (12p) of sequence GRRPGGWWMR. Single-aa mutagenesis identified three residues as significant
for the binding of 12p to BCD-F9 Ab. Rabbits immunized with this peptide produced specific antisera
that inhibited the binding of BCD-F9 to HT-1080 cells in vitro and elicited antitumor activity against
experimental metastasis in vivo [54].
In this same context, BAT is a monoclonal Ab that binds an uncharacterized 47–50 kDa
membrane protein. The anti-tumor activity of BAT is mediated by its immunostimulatory properties,
as demonstrated by adoptive transfer experiments in which splenocytes from BAT-treated mice
induced regression of tumors in receiving mice [55]. By panning a phage-displayed peptide library
on BAT, two mimotopes, Peptide A (PRRIKPRKIMLG) and B (QKILQQINLPRI), were isolated and
characterized in competition assays on Daudi cells. In vivo, both peptides induced Abs capable of
stimulating peripheral blood lymphocyte proliferation and IFN-γ secretion. Despite the relatively
low titers, these Abs induced significant cytolytic activity of lymphocytes against both natural killer
(NK)-sensitive and NK-resistant tumor cells. Immunization prevented the development of lung foci in
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mice inoculated intravenously with B16 melanoma cells, similar to what was observed following BAT
treatment [28]. A successive study demonstrated that location, morphology, and inflammation of the
lung metastases were similar in all groups (untreated, BAT-treated, and peptide-immunized mice).
So, it was concluded that peptide treatment eliminates circulating tumor cells rather than exerting a
tumoricidal effect in the lungs [56].
2.6. Mimotopes of Tumor-Associated Carbohydrate Antigens
Cancer cells are known to bear aberrant glycosylation profiles that affect both local invasion and
metastatic spreading. A unique advantage of these tumor-associated carbohydrate antigens (TACAs)
is that multiple proteins and lipids on cancer cells are tagged by the same carbohydrate structure;
thus, targeting TACAs has the potential to raise an immune response against a broad spectrum of
antigens. Glycans, however, are among the most challenging targets for vaccine design because
of their poor immunogenicity. Peptide mimotopes of carbohydrates (also called glycoreplicas) are
potentially suitable to overcome this limitation [57]. One of the first attempts to identify carbohydrate
mimotopes goes back to 1997, when a phage-displayed 15-mer library was employed to screen Abs
AD117m and H11, recognizing the neutral glycosphingolipids lactotetraosylceramide (Lc4Cer) and its
isomer neolactotetraosylceramide (nLc4Cer), respectively. The two independent screenings provided
sequences sharing high similarity and one identical motif (RNVPPTFNDVYWIAF), suggesting strong
similarity between the antigen-binding sites of these Abs. Corresponding synthetic peptides were
produced and confirmed as functional mimotopes [58].
Another group of glycosphingolipids, gangliosides include one or more negatively-charged
sialic acid residues (N-acetylneuraminic acid, NANA). Panning the anti-GD1α ganglioside Ab KA17
with a 15-mer phage display library provided four specific phage clones. One of the selected motifs,
WHWRHRIPLQLAAGR, interacted specifically with GD1+ RAW117-H10 murine highly metastatic
lymphoma cells and inhibited their adhesion to hepatic sinusoidal endothelial cells. In vivo, intravenous
injection of WHWRHRIPLQLAAGR led to an almost complete inhibition of RAW117-H10 metastasis
to lung and spleen, and ~50% inhibition of liver metastasis [59]. GD2 is another ganglioside with
TACA-like properties since it is highly expressed on tumor cells while having a restricted distribution
in normal tissues except for neurons, skin melanocytes, and peripheral pain fibers. Overexpression of
GD2 on highly malignant tumors such as neuroblastoma, a mostly fatal neoplasm in pediatric oncology,
is yet another reason why GD2-mimicking peptides are often searched. Panning the anti-GD2 Ab
14G2a with a 15-mer phage-displayed library, followed by molecular modeling and mutagenesis
studies, led to the identification and characterization of peptide 47-LDA (EDPSHSLGLDVALFM) as a
mimotope of GD2. Immunization of BALB/c mice with a plasmid encoding 47-LDA resulted in the
production of GD2-reactive Abs, which triggered complement-dependent cytotoxicity in vitro and
protected against subcutaneous growth of human GD2-positive MV3 melanoma cells in vivo [60].
The 47-LDA vaccine also activated potent CD8+ T-cell responses when delivered simultaneously or
1 day after challenge with GD2+ syngeneic NXS2 neuroblastoma cells. Adoptive immunotherapy
with CD8+ T lymphocytes isolated from 47-LDA-immunized and cured mice, in combination with
plasmid-derived interleukin 15 (IL-15) and IL-21, led to regression of NXS2 tumors and prolonged
tumor-free survival [61]. Further studies showed that the anti-GD2 Ab 14G2a cross-reacts with a
105 kDa glycoprotein expressed by murine and human neuroblastoma and melanoma cells, identified
as activated leukocyte cell adhesion molecule (ALCAM/CD166). Stable silencing of CD166 expression
in GD2-negative Neuro2a cells by CD166-specific short-hairpin RNA (shRNA) not only decreased the
reactivity of these cells against 14G2a Ab, but also abolished recognition by 47-LDA vaccine-induced
CD8+ T lymphocytes [62,63].
Selective motifs have also been identified by panning a 12-mer library of general formula xCx8Cx
on the anti-GD2 Ab 14G2a. Five peptides (#8, NCDLLTGPMLCV; #65, SCQSTRMDPNCW; #85,
VCNPLTGALLCS; #94, RCNPNMEPPRCF; and #D, GCDALSGHLLCS) have proven to specifically
inhibit the binding of 14G2a to the human neuroblastoma cell line IMR-32 [64]. Among other
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Abs developed against GD2, the chimeric monoclonal ch14.18 is of interest since it has been
demonstrated to recognize GD2+ neuroblastoma cells in the body when injected intravenously.
From a constrained 10-mer phage-displayed library challenged on ch14.18, thirteen peptides
were isolated and their specificity was validated in competitive binding assays with the natural
antigen [65]. The GD2-mimicking properties of two such peptides (MD, CDGGWLSKGSWC and
MA, CGRLKMVPDLEC), expressed and purified as recombinant proteins, were further investigated
in docking experiments with ch14.18. In addition, the effect of GD2 mimotope was evaluated in
peptide- and DNA-vaccination protocols, showing that mice treated with DNA vaccines develop
GD2-specific innate cellular immune responses and are protected from spontaneous liver metastases in
a neuroblastoma model [66]. The same group also worked on mimotope optimization by systematic
alteration of the aa sequence with the SPOT technology, which is based on the synthesis of a defined
peptide library onto a solid phase. MA peptide was subjected to systematic replacement of each aa
within the mimotope sequence, leading to identification of C3, a peptide variant with a 5.6-fold lower
Kd value. C3-KLH vaccine specifically suppressed primary tumor and spontaneous metastasis in a
syngeneic model of neuroblastoma. Moreover, it induced an anti-tumor immune response characterized
by systemic circulation of anti-GD2 IgGs [67]. In a further work, a 15-mer phage-displayed library
was panned on another GD2-specific Ab, ME361. Based on the ability to inhibit the binding of ME361
to GD2, two peptides (LDVVLAWRDGLSGAS and GVVWRYTAPVHLGDG) were coupled to either
KLH or multiple antigenic peptide (MAP) and tested in immunization experiments. Vaccination with
these peptides (i) induced production of anti-GD2 Abs, (ii) triggered a delayed-type hypersensitivity
response, and (iii) protected against tumor challenge with GD2+ melanoma cells [68]. Similarly,
the anti-GD3 Ab 4F6 was panned with a 15-mer phage-displayed library and four sequences (GD3P1,
LAPPRPRSELVFLSV; GD3P2, PHFDSLLYPCELLGC; GD3P3, GLAPPDYAERFFLLS; and GD3P4,
RHAYRSMAEWGFLYS) were selected. GD3P4 was chosen as the most efficient and tested in vivo,
where a MAP version of this peptide triggered the production of anti-GD3 Abs [69].
A widely recognized TACA, the tumor-associated carbohydrate Thomsen–Friedenreich antigen
(TF-Ag) is overexpressed on the surface of several types of tumor cells, where it contributes to
cell adhesion and migration during the metastatic spreading. Panning the anti-TF-Ag JAA-F11 Ab
with a 12-mer library led to the identification of five peptide motifs (D2, HIHGWKSPLSSL; B1,
HHSHKTNLATTP; B6, GHPHYITHKPNR; C1, YPSLPVYHSLRS; and D1, MHKPWSGHMQVP).
D2 was further investigated for its binding specificity in several in vitro assays. In vivo, all the peptides
were able to induce the production of specific Abs, in support of their development as potential
anti-cancer vaccines [70]. In a more recent work, a phage display panning was performed on UN1,
a Ab against CD43 glycoforms specifically expressed in lymphoblastoid T-cell lines and solid tumors,
included breast, colon, gastric, and lung carcinomas. A total of 153 clones were positive to the UN1
Ab, 28 of which bound the Ab with high affinity and were sequenced to identify 11 unique motifs.
Two peptides (W15, TCKLLDECVPLW and G23, SFAATPHTCKLLDECVPLWPAEG) were further
characterized. In immunization experiments, a phage displaying the G23 sequence (named 2/165
phagotope) was capable of inducing a specific Ab response in BALB/c mice [71].
All these studies, although with somehow contrasting results, suggest that TACA mimotopes
may be valuable in the development of therapeutic or even prophylactic cancer vaccines. However,
antigenic mimicry (i.e., competition for binding the same Ab) not always means that the response is
cross-reactive with a glycan moiety. Because carbohydrates and peptides are very different biochemically,
further studies will be necessary to translate these results to the clinic [57].
2.7. Conclusions for this Section
Mimotope-based vaccines appear promising. However, despite the encouraging results
summarized here, to our knowledge only one peptide derived from phage display screenings is
as yet being investigated in clinical trials. This peptide, of sequence WRYTAPVHLGD (P10s), is a
rational evolution of GVVWRYTAPVHLGDG (P10original) described by Wondimu and colleagues [68]
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as a glycoreplica motif binding the anti-GD2 Ab ME361. P10s, conjugated to the Pan T lymphocyte
peptide PADRE, was initially designed for treatment of high-risk/recurrent breast cancer in a cohort
of six patients. Preliminary data showed that the Ab response induced by the vaccine may improve
chemotherapy efficacy and affect metastatic lesions in these patients [72,73]. Presently, other clinical
trials are recruiting patients to evaluate P10s-PADRE in advanced stage lung cancer, stage IV
breast cancer, and triple negative breast cancer (Highlands Oncology Group, Fayetteville, Arkansas,
United States and University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States.
Data from www.clinicaltrials.org). If these trials confirm the clinical benefit of vaccination with
P10s-PADRE, many others will probably follow and bring to full potential the huge amount of
preclinical data that are still waiting to be developed. A list of peptide mimotopes described in this
section, with reference to the Ab panned and the peptide motif isolated, is provided in Table 1.
Table 1. Mimotopes of tumor-associated antigens.
Target Ab Peptide Motif Reference
CD20 Rituximab
ITPWPHWLERSS [29]
QDKLTQWPKWLE [30]
WPxWLE
(A/S)NPS [31]
WAANPS
PYANPSL [33]
WPKWLE
PYANPSL [34]
EGFR
Cetuximab CQFDLSTRRLKCCQYNLSSRALKC [35]
Cetuximab, Matuzumab KTLYPLG [37]
12H23, Ch806 WHTEILKSYPHELPAFFVTNQTQD [38]
ICR-62 QHYNIVNTQSRV [39]
Panitumumab DTDWVRMRDSARVPGWSQAFMALA [41]
ErbB2
Trastuzumab
CQWMAPQWGPDC [42]
WxxGxAxGS [43]
L26, N12, L288 ALVRYKDPLFVWGFL [44]
SER4 INNEYVESPLYM [45]
PSA 4G5
VDPGKYNKY
EGPAKGFKL
GCYEAPSKAAKC
[46]
RRSHPCRTCTTHTP
HRKTTCTRCPATSP
HRRGECRACPLLPA
RRPAHCHHCPRNP
[47]
CEA Col-1 DRGGLWKTP [17]
VEGF Bevacizumab DHTLYTPYHTHP [48]
Gastric antigen MGb1 MGb1 HxQLxS [49]
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Table 1. Cont.
Target Ab Peptide Motif Reference
Gastric antigen MG7 MG7
NAIYARNAQ
TCHLRVYAQ
SWAPVYARN
[50]
KPHVHTK [51]
KPHLHFH
KPHSHLH
SWAPVYARAN
[53]
Human fibrosarcoma cell line BCD-9 GRRPGGWWMR [54]
Human B lymphoblastoid cell line BAT PRRIKPRKIMLGQKILQQINLPRI [28,55,56]
Lc4Cer, nLc4Cer AD117m, H11 RNVPPTFNDVYWIAF [58]
GD1α KA17 WHWRHRIPLQLAAGR [59]
GD2
14G2a
EDPSHSLGLDVALFM [60,61]
NCDLLTGPMLCV
SCQSTRMDPNCW
VCNPLTGALLCS
RCNPNMEPPRCF
GCDALSGHLLCS
[64]
ch14.18 CDGGWLSKGSWCCGRLKMVPDLEC [65–67]
ME361 LDVVLAWRDGLSGASGVVWRYTAPVHLGDG [68]
GD3 4F6
LAPPRPRSELVFLSV
PHFDSLLYPCELLGC
GLAPPDYAERFFLLS
RHAYRSMAEWGFLYS
[69]
TF-Ag JAA-F11
HIHGWKSPLSSL
HHSHKTNLATTP
GHPHYITHKPNR
YPSLPVYHSLRS
MHKPWSGHMQVP
[70]
Tumor-specific CD43 glycoforms UN1 TCKLLDECVPLWSFAATPHTCKLLDEC-VPLWPAEG [71]
3. Phages as Nanocarriers for Anticancer Vaccines
In cancer vaccination, either a TAA or a TAA-mimic molecule (mimotope) is presented to the
patient’s immune system to prime and/or boost an immune response. In the case of mimotopes,
this response may be directed against a synthetic/soluble peptide (as the ones described in the previous
section) or against a peptide genetically or chemically anchored to the phage surface. A study focused
on how the humoral response is raised in this setting demonstrated that (i) conjugation of a peptide
with a phage particle gives a better response than conjugation with another carrier, e.g., ovalbumin
(OVA), and (ii) modification of the phage coat protein to decrease its complexity and immunogenicity
retargets the immune response to the peptide [74]. A schematic representation of Ab-based responses
triggered by either free or phage-displayed TAAs (or their mimotopes) is presented in Figure 1.
The use of phages as vaccine carriers, in addition, may provide some benefits in the induction
of a cellular response due to the nature of phages themselves. Being recognized as foreign antigens,
phage particles per se induce an immunogenic response in humans by activating the innate immune
system and eliciting adaptive immunity [75]. Phage-displayed peptides are processed and exposed
on the MHC, leading to stimulation of both CD4+ (MHC II) and CD8+ (MHC I) T lymphocytes and
Molecules 2020, 25, 843 11 of 28
induction of strong cytotoxic responses, a key feature for vaccines in general and for anticancer vaccines
in particular [76–78] (Figure 2).
Figure 1. Humoral response: B lymphocytes. Both TAA-mimic peptides and TAA-displaying phage
particles are recognized by B lymphocytes, which respond by producing high-affinity, anti-TAA Abs.
These Abs are released and enter the bloodstream to reach tumor cells and tag them for neutralization
and/or destruction. Abbreviations: TAA, tumor-associated antigens.
Figure 2. Cellular response: APCs and T-lymphocytes. TAA-displaying phages are processed inside
an APC via the endosome-lysosome pathway. The TAA is exposed on the APC surface complexed
with MHC molecules. Naïve T lymphocytes carrying a TAA-specific TCR are activated by interaction
with the TAA-MHC complex: binding to MHC class II leads to activation of CD4+ T lymphocytes and
differentiation in Th cells, while binding to MHC class I leads to activation of CD8+ T lymphocytes and
differentiation in CTLs. Both types of effector T cells release chemokines and cytokines to mount an
immune response against the TAA. Abbreviations: APC, antigen-presenting cell; TAA, tumor-associated
antigen; MHC, major histocompatibility complex; TCR, T-cell receptor; Th, T helper; CTL, cytotoxic T
lymphocyte; IL-2, interleukin 2; IFN-γ, interferon γ; TNF-α, tumor necrosis factor α.
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When administered intravenously, phages extravasate from the circulation and penetrate into
tissues including tumor masses, thus representing a convenient route for vaccine administration.
Last but not least, studies suggest that phages are non-toxic to animals [79], and in some case also to
humans (see, e.g., [80]), and therefore unlikely to cause adverse effects. Several phage-based vaccines
have been proposed for use in diverse biomedical applications (reviewed in [81–83]). They include
different phage strains (e.g., T4 and λ) in addition to the most widely employed display system
(the M13-derived filamentous bacteriophage fd), with peculiar features and specific capabilities to
stimulate the host’s immune system [84].
3.1. Phage Particles Displaying Antigenic Portions of Melanoma Antigen Gene and Related Proteins
Melanoma antigen gene (MAGE) family consists of several chromosome X-linked genes first
identified as they encode tumor antigens recognized by CTLs. MAGE proteins are present in several
types of human cancer but not in normal tissues, thus representing potentially valuable TAAs.
An antigenic MAGE-A1 nonapeptide of sequence EADPTGFSY (MAGE-A1161–169) was expressed as a
fusion with the fd major coat protein pVIII and the deriving hybrid virion was tested for its capacity
to induce immune responses. In vitro, both wild-type and MAGE-A1161–169-phages elicited stronger
delayed time hypersensitivity responses and enhanced NK cell activity. However, only splenocytes
derived from mice immunized with MAGE-A1161–169-phages (but not from those immunized with
wild-type phages) exhibited lytic activity against B16-F10 murine skin melanoma cells. In vivo, two trials
were performed to determine whether MAGE-A1161–169-phages can (i) protect against tumor grafting
(prevention) and/or (ii) inhibit the growth of established tumors (immunotherapy). For these prevention
and immunotherapy trials, C57/BL6J mice were injected with the phage vaccine a few weeks prior
to, or 5 days after, subcutaneous implant of B16-F10 cells, respectively. In both cases, vaccination
with MAGE-A1161–169-phages resulted in controlled tumor growth and prolonged overall survival
compared with wild-type phage [85]. Similarly, the work from Sartorious and colleagues describes an
antigen delivery system in which p23 (KDSWTVNDIQKLVGK) (a promiscuous HLA-DR-restricted
T-helper peptide) and either MAGE-A10254–262 (GLYDGMEHL) or MAGE-A3271–279 (FLWGPRALV)
(both HLA-A2-restricted TAAs) are fused to the fd phage pVIII protein, creating the hybrid virions
fd23/Mg10 and fd23/Mg3, respectively. In vitro, peripheral blood mononuclear cells (PBMCs)–used as
a model of APCs—induced specific T-lymphocyte cytotoxic responses when pulsed with fd23/Mg10.
Treatment with wild-type phages in the presence of soluble p23 and MAGE-A10254-262 had no effect,
suggesting that a complete virion is necessary to induce cytotoxicity. Similarly, a cytotoxic activity
was observed in splenocytes from mice immunized with either fd23/Mg10 or fd23/Mg3. In vivo,
HHD transgenic mice [86] were vaccinated with fd23/Mg3 and then challenged with syngeneic
EL-4-HHD lymphoma cells overexpressing MAGE-A3. At day 21, a tumor was present in 100% of
control mice, but only in 36% of fd23/Mg3-immunized mice. At day 80, 60% of fd23/Mg3-immunized
mice were still alive, while all control mice died between day 34 and 60 [87]. In another work,
circulating Abs from a breast cancer patient were immobilized on protein G-coupled magnetic beads
and used to immunocapture potential TAAs, retrieving MAGE-1 among others. Oral immunization
of BALB/c mice with T7 phages exposing a selection of identified TAAs (MAGE-1-T7, SSX2-T7,
or p53-T7) induced effective Th1 and Th2 responses against the antigens. Another selected TAA
(Hsp27) was expressed as a fusion with the capsid protein of phage T7 and the deriving hybrid
vector was used to immunize BALB/c mice, followed by subcutaneous implant of syngeneic 4T1
breast adenocarcinoma cells. Average tumor weights and metastasis number in mice immunized with
Hsp27-T7 were significantly lower than in the controls, supporting a preclinical efficacy of this T7
phage-based vaccine [88]. A murine gene sharing several characteristics with human MAGEs, P1A was
identified as encoding a protein specifically recognized by a clone of CD8+ T lymphocytes raised
against the murine mastocytoma P815 model. P1A includes a nonapeptide (LPYLGWLVF, P1A35–43)
that binds to the MHC I determinant H-2d to generate antigen P815AB, a target for immune responses
against tumor P815. Hybrid fd-derived virions displaying P1A35–43 and a 6x-histidine tag fused to
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the pVIII protein (pC89hisP1A) were prepared. Splenocytes from mice immunized with pC89hisP1A
exhibited specific anti-P1A cytotoxic responses. T lymphocytes from the same mice produced high
levels of IFN-γ, mostly (75%) released by CD4+ cells, revealing the generation of Th1-dominated
immune responses. In an in vivo prevention trial, pC89hisP1A was administered subcutaneously to
DBA/2 mice prior to implant of P815-F3 cells. While no control animal survived after day 60, 70% of
pC89hisP1A-immunized mice were still alive, demonstrating prophylactic efficacy. Similarly, in an
immunotherapy trial DBA/2 mice challenged with pC89hisP1A four days after implant of P815-F3 cells
showed prolonged survival and delayed tumor growth (with 2 out of 30 mice being cured), in support
of a therapeutic efficacy of the vaccine [89]. Despite the promising results, to our knowledge there has
not been any follow up to such preclinical studies.
3.2. Phage Particles Displaying Antigenic Portions of HER2
As described in the previous section, HER2 has been the subject of several studies involving
phage display in the context of immunotherapy. Some specific sequences of HER2 are sufficiently
immunogenic to stimulate CTLs to recognize and kill HER2+ cancer cells, and have therefore been
investigated in both preclinical and clinical settings. Recent papers from Behravan group describe
the engineering and testing of phage-based vaccines that include one of two HER2-derived peptides,
E75 (HER2369–377, KIFGSLAFL) [90] and AE37 (HER2776–790, GVGSPYVSRLLGICL) [91], previously
investigated as candidate vaccines in clinical trials for breast, ovarian, and prostate cancer [92–99].
E75 peptide was exposed on λ phage particles as a fusion with the gpD coat protein and the deriving
virions λF7(gpD::E75) were used to immunize BALB/c mice. High levels of IL-4 (associated to humoral
immunity) and IFN-γ (associated to cellular immunity), as well as increased levels of CD8+ cells,
were detected in sera from immunized mice. Splenocytes from the same mice showed specific cytotoxic
activity against HER2+ TUBO mouse mammary tumor cells in vitro. Both preventive and curative
effects were investigated in vivo in BALB/c mice implanted with TUBO cells. While λF7(gpD::E75)
failed in the prevention trial, the curative trial was somehow successful in delaying tumor growth [90].
In the other work, the same experiments were repeated with λ phages exposing AE37 [λF7(gpD::AE37)],
obtaining similar in vitro results. In vivo, λF7(gpD::AE37) was more efficient than λF7 (gpD::E75): not
only curative but also prophylactic effects were observed [91].
3.3. Phage Particles Displaying Antigenic Portions of Mucin 1
The transmembrane protein mucin 1 (MUC1) is a functional target for anticancer approaches
and a likely valuable TAA for immunotherapy. In normal cells, MUC1 is heavily glycosylated, so its
antigenic epitopes are shielded from the immune system; in contrast, MUC1 is under-glycosylated
and overexpressed (~100-fold) on the surface of cancer cells. The extracellular domain of MUC1
consists of tandem repeats of a 20-aa motif (PDTRPAPGSTAPPAHGVTSA), where the serine and
threonine residues represent anchor points for O-glycosylation. In cancer cells, the threonine close to
the C-terminal of the motif is linked to N-acetyl-galactosamine creating a TAA referred to as Tn antigen.
Phage Qβ has been exploited to generate non-infective virions known as virus-like particles (VLPs),
which can be chemically conjugated with peptides or even with large and complex proteins [100].
VLPs carrying antigenic epitopes have proven to be immunogenic, thus representing good candidates
for vaccine development. In a recent work by Yin and colleagues [101], MUC1 peptides with different
glycosylation patterns were linked to Qβ phage, the deriving Qβ-MUC1 conjugates were administered
to C57/BL6 mice, and the induction of specific Abs was investigated. Huge titers of Abs were generated,
with broad selectivity for different glycosylation patterns of MUC1 as demonstrated by ELISA and
microarray analysis. These Abs were able to bind MUC1-expressing tumor cells and kill them by
complement-mediated cytotoxicity. Splenocytes and lymph node cells from mice immunized with
Qβ-MUC1 induced CTL responses both in vitro and in vivo [101].
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3.4. Phage Particles Displaying Antigenic Portions of VEGFR2
On the one hand, self-antigens in tumor masses tend to be quantitatively (overexpression) more
than qualitatively (mutation) different from those in normal tissues, and this feature leads to immune
tolerance against the TAA. On the other hand, because of potential induction of self-immunity,
targeting those antigens has been mostly neglected until recently [102]. Despite these drawbacks,
immunotherapy directed to self-antigens is now emerging as a promising approach in cancer therapy.
VEGFR2 is the major receptor for VEGF and mediates numerous signal pathways in angiogenesis,
such as microvascular permeability, endothelial cell proliferation, invasion, migration, and survival.
VEGFR2 is often overexpressed in tumor endothelial cells, therefore representing a potentially suitable
TAA. A VEGFR2-based vaccine was created by displaying the extracellular portion of mouse VEGFR2
protein (mVEGFR2) on the surface of phage T4. ELISA and Dot ELISA assays confirmed the presence
of anti-mVEGFR2 Abs in the sera of immunized mice, which were able to inhibit capillary-like tube
formation in an in vitro angiogenic assay with human umbilical vascular endothelial cells (HUVECs).
In vivo, both prophylactic immunization with T4-mVEGFR2 and adoptive transfer of purified Abs
from T4-mVEGFR2-immunized mice to Lewis lung carcinoma-bearing mice resulted in inhibition of
tumor growth and prolonged survival. Further results suggest that the T4-mVEGFR2 vaccine exerts its
anti-tumor activity mainly through CD4+ T lymphocytes. In the discussion, the authors speculate that
using T4 as a vaccine carrier may circumvent the immune tolerance to VEGFR2 thanks to the high
immunogenicity of the viral coat proteins [103].
3.5. Phage Particles Exposing Phage Display-Derived TAA Mimotopes (Miscellaneous)
As described previously, phage-displayed libraries are screened to isolate mimotopes—peptides
that mimic the secondary structure and antigenic properties of a protein, carbohydrate, or lipid.
Because such mimotopes are selected as the best fit for specific anti-TAA Abs, they are expected to be
at least as efficient as, and likely more than, natural TAA epitopes. For example, the EM.L2 peptide
(QHYNIVNTQSRV), previously identified as an EGFR mimotope specific for the IRC-62 Ab [40],
was expressed as a fusion with the L2 extracellular domain of human EGFR, a 6x His tag, and the
pVIII protein of fd phage. The deriving peptide-displaying phages were tested in a mouse model of
Lewis lung carcinoma, confirming the induction of specific anti-EM.L2 Abs. Following vaccination
with EM.L2-displaying phages, both humoral and cellular responses were activated, as demonstrated
by increased levels of IL-4 and IFN-λ. In vivo, the EM.L2-displaying phage was tested as both a
prophylactic and therapeutic vaccine in a model of Lewis lung carcinoma. In both settings, tumor growth
was inhibited, although not fully blocked, in the prophylactic trial [104].
In another work, a phage display panning was designed to identify new immunogenic and
tumor-targeting peptides. Panning was performed firstly in vivo in C57BL/6 mice bearing B16-F10
syngeneic skin melanoma tumors (a highly aggressive and poorly immunogenic model), followed
by additional rounds of selection on suspended B16-F10 cells in vitro. A phage designated WDC-2
(displaying the TRTKLPRLHLQS peptide motif) proved to be a specific ligand of B16-F10 cells and
was therefore chosen for further investigation. When tumors reached a palpable volume, mice were
injected peritumorally with either the WDC-2 phage or a control (PBS or a non-specific Fab-exposing
phage). No mice survived more than 18 days in the control groups; in contrast, 20% of the mice
immunized with WDC-2 phage survived up to 30 days. In other experiments performed in B16/A2Kb
tumor-bearing mice, WDC-2 phage was compared with an HLA-A2-specific Fab-phage, observing
complete regression of established tumors and long-term survival in 42 or 53% of mice, respectively.
Immunohistochemistry of tumor sections revealed massive neutrophil infiltration within 24 h from
injection. In vitro, phages induced IL-12 and IFN-γproduction in mouse splenocyte cultures. In addition
to these immune responses, the authors suggest that an unspecific antiviral inflammation may be
triggered by phage treatment, thus contributing to tumor regression [79].
In a study by Samoylov and colleagues, phage display was used to identify mimotopes of the
gonadotropin releasing hormone (GnRH), with the intent to stimulate an endogenous production of
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therapeutic Abs. Polyclonal anti-GnRH Abs (either commercial or purified from cat and dog sera)
were subjected to panning with a 8-mer library expressed as a fusion with the pVIII protein of fd
phage. Clones displaying potential GnRH mimotopes (peptide motifs: EGLRPSGQ, DGLRPQAP,
EHPSYGLA, EPTSHWSA, and DAPAHWSQ) were chosen based on their sequence similarities to
GnRH and tested for their capability to induce the production of specific Abs in mice. Among these,
EHPSYGLA was identified as the motif triggering the most long-lasting humoral responses, although in
this preliminary trial no functional outcome (i.e., suppression of testosterone levels in the blood) was
observed. Additional in vivo studies were performed with EHPSYGLA-phage either at higher doses or
in combination with a a poly(lactide-co-glycolide) (PLGA)-based adjuvant, demonstrating a multifold
increase in Ab production paralleled by a substantial decrease in the production of testosterone.
Immunization of mice with EHPSYGLA-phage, even at the highest doses, resulted in no adverse effect.
While the main purpose of this research group remains animal contraception, an approach similar
to the one described in this paper—as suggested by the authors themselves—might be useful in the
treatment of human hormone-sensitive cancers of the reproductive trait [105].
3.6. Clinical Trials with Phage-Based Anticancer Vaccines
As of today, entering “phage” in the American database of clinical trials (www.clinicaltrials.gov)
returns 42 records, most of which are focused on infectious diseases. Current research mainly explores
the lytic property of phages and their proteins to develop treatments for antibiotic-resistant bacterial
infections [106]. Only one study (NCT02757755, concluded in 2016) included phage as the main
component, but the scope was a mere biosafety evaluation. A single report of a European phase
I/II clinical trial on patients treated with a phage-based vaccine (MKI-TR02/2002) was published in
2014 [107]. The trial follows a preclinical study in which a selected B-cell receptor—Ig variable region
peculiarly exposed by each malignant B-cell clone, also called idiotype—was chemically linked to
the surface of phage particles. The deriving Id-phages were tested in immunization experiments
in BALB/c mice either tumor-free (tolerance and dosage experiments) or bearing syngeneic BCL1
lymphomas (efficacy studies), demonstrating both safety and tumor protection [108]. Following
preclinical toxicity studies in mice and rabbits, the Id-phage was also evaluated as a potential vaccine
in patients. Fifteen adults with terminal-stage multiple myeloma were subjected to a total of six
intradermal immunizations (day 1, 7, 14, week 4, 8, 12), with the Id-phage vaccine in the presence
of KLH as an immunogenic carrier and GM-CSF as an immunostimulatory adjuvant. The initial
Id-phage dose of 0.25 mg for patients 1–5 was subsequently escalated to 1.25 mg for patients 6–10 and
2.5 mg for patients 11–15, as no serious adverse event occurred. Phage vaccination was well-tolerated
with only minor and transient side effects, such as skin irritation at the injection site and flu-like
symptoms. The efficacy of vaccine treatment was evaluated as decrease in serum paraprotein (M level)
and urine-excreted myeloma-specific light chains, followed by characterization of humoral (titer of
anti-idiotype Abs) and cellular responses (CTL and delayed type hypersensitivity). Patients exhibiting
a clinical response to Id-phage vaccine also produced anti-idiotype Abs. Due to high tumor load and
impaired immune function, these patients were not expected to respond to active immunotherapy;
nevertheless, the Id-phage vaccine induced a clinical response in most of them. Further studies with a
larger cohort of patients will be necessary to confirm these data and confer statistical significance to
these potentially interesting results [107].
3.7. Conclusions for this Section
Phages exert immunomodulatory effects and may be efficiently exploited in the design of clinical
applications. However, the continuous/repeated administration of phages is expected to induce memory
cells with subsequent generation of anti-phage Abs. So, it is generally accepted that the utilization of
phages either for the production of new therapeutics, as gene delivery vehicles, or as tumor targeting
agents (at large, for any clinical purpose) must be carefully evaluated as per their immunogenicity and
retention time [75]. Among potential drawbacks, circulating phages are inactivated by macrophages of
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the reticuloendothelial system in synergy with anti-phage Abs. In addition, while phage preparations
administered per os may downregulate the antigen processing abilities of intestinal dendritic cells,
phages administered intravenously are rapidly cleared by liver cells [109,110]. There is a general lack of
knowledge as to the fate of phages in the human body in terms of cellular interactions [111]. For example,
the presence of circulating phages (“phagemia”) may have as yet unknown functional consequences.
To our knowledge, there are only two reports confirming a natural phage occurrence in human sera
(i.e., unrelated to their exogenous administration) [112,113]. Another example is phage uptake after oral
administration, which requires more study since the few results available are discordant. The presence
of phages within the gastrointestinal tract, often in significant numbers, raises the possibility of their
interactions with enterocytes and gut-associated lymphoid tissue, an immunological network that
includes the majority of T lymphocytes and a significant proportion of B lymphocytes [109]. Most of all,
the influence of phages on the immune system remains poorly understood. A list of the phage-based
vaccines described in this section, with reference to the antigenic epitope displayed, the phage carrier,
the peptide motif, and the animal model investigated, is provided in Table 2.
Table 2. Phages as nanocarriers for anticancer vaccines.
Antigen Epitope Phage Peptide Motif Model Reference
MAGE
MAGE-A1161–169
pfd8wf
(fd derivative) EADPTGFSY
B16-F10
melanoma [85]
MAGE-A10254–262
fd23
(fd derivative) GLYDGMEHL
EL-4-HHD
lymphoma [87]
MAGE-A3271–279
fd23
(fd derivative) FLWGPRALV
EL-4-HHD
lymphoma [87]
MAGE-1 T7 Entire antigen 4T1 breastcarcinoma [88]
P1A P1A35–43
pc89
(fd derivative) LPYLGWLVF
P815
mastocytoma [89]
HER2
HER2369-377 λ KIFGSLAFL
TUBO breast
carcinoma [90]
HER2776-790 λF7 GVGSPYVSRLLGICL
TUBO breast
carcinoma [91]
MUC1 MUC1 Qß PDTRPAPGSTAPPAHGVTSA Non tumoral [101]
VEGFR2 VEGFR2 T4 Extracellular portion Lewis lungcarcinoma [103]
EGFR EGFR M13-pAK8-VIII(fd derivative) QHYNIVNTQSRV
Lewis lung
carcinoma [104]
Cell line Unknown M13KE(fd derivative) TRTKLPRLHLQS
B16/A2Kb
melanoma [79]
GnRH GnRH f8-8(fd derivative) EHPSYGLA Non-tumoral [105]
Tumor idiotype
B-cell receptor M13K07(fd derivative) Entire antigen
BCL1
lymphoma [108]
Different myeloma
idiotypes
M13K07
(fd derivative) Entire antigen
Clinical trial
in patients [107]
4. Phage Display-Derived Peptides as Nanomodulators of the Immune Response
As small molecules easy to characterize and produce on a large scale, peptides are promising
tools for targeted approaches in cancer immunotherapy. Initial studies investigated the use of peptides
to stimulate the immune system indirectly. Successive reports focus on two main applications:
interfering with immune checkpoints and modulating the activity of immune cells. These approaches
are schematized in Figure 3.
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Figure 3. Phage display-derived peptides as nanomodulators of the immune response. Peptides
administered intravenously can exit the blood vessels and reach different cell types to (1) inhibit
PD-1/PD-L1 interaction or (2) target immune cells for either activation (dendritic cells, monocytes,
λδT lymphocytes) or inhibition (Tregs, M2-like macrophages) of their functions. (3) Selected peptides
can also be exploited in a CAR strategy. Abbreviations: PD-1, programmed cell death 1; PD-L1,
programmed cell death ligand 1; CTL, cytotoxic T lymphocytes; CDR, complementary determining
region; Tregs, T regulatory cells; CAR, Chimeric Antigen Receptor.
4.1. Targeting the Immune System Indirectly
Early applications of phage display-derived peptides to stimulate the immune system against
cancer cells started with the search for ligands of the IgM λ receptor on lymphoma cells. This receptor
is unique to each patient, therefore the use of therapeutic anti-idiotypes, despite initially promising,
has proven unpractical because the selection and optimization of monoclonal Abs remain time- and
money-consuming procedures. As an alternative, by panning three phage-displayed libraries (based on
random 8- or 12-mer motifs) on the IgM λ receptor expressed by the human Burkitt lymphoma cell line
SUP-B8, Renschler and colleagues isolated several clones sharing one of the four consensus sequences
KP–xRV, -W–WxR, Y–EDLRRR, and –PVDHGL. The first three were optimized by mutagenesis and the
specificity of derived peptides (named A, B, and C) was confirmed by ELISA. Corresponding polymers
of biotin-peptides bound to streptavidin induced specific cytotoxicity of SUP-B8 cells, paralleled by
intracellular protein phosphorylation signaling [114]. In a successive study, the same group explored
the use of these peptides for immunotherapy of B-cell lymphoma. Activation of SUP-B8 cells was
quantified as acidification of the extracellular medium. In these assays, peptide B (DWAIWSKRGGK)
and C (YSFEDLYRRGGK) showed comparable efficacy, being peptide C active at slightly lower doses.
This was the first evidence that B-lymphoma cells can be activated by peptide ligands in addition to
anti-idiotype Abs [115].
In another set of experiments, melanin was chosen as a target. This protein is released by
melanocytes with altered membrane permeability or undergoing cell death (such as in melanomas) and
so it represents a potential TAA that can be accessed through the blood circulation. By panning a 7-mer
library on recombinant melanin, twenty-four individual clones were identified, eight of which proved
to be specific binders and three (HTTHHRN, TTHQFPF, and NPNWGPR) were further investigated.
Each peptide was individually linked to 188Re via the crosslinker hydrazinonicotinamide (HYNIC)
and validated for selective binding to the highly melanized human melanoma cell line MNT1. In vivo,
administration of 188Re-HYNIC-NPNWGPR to A2058 human metastatic melanoma-bearing nude mice
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resulted in retardation of tumor growth. The unlabeled version of NPNWGPR was almost as efficient
as the 188Re-HYNIC–peptide, suggesting that the observed therapeutic effect was independent from
the attached radionuclide. The work led to the speculation that melanin-specific peptides are absorbed
by melanin on the cell surface, where they become immunogenic and trigger a localized inflammation
responsible for the antitumor effect [116].
4.2. Targeting the PD-1/PD-L1 Axis with Peptide Inhibitors
One of the most characterized immune checkpoint pathways, the PD-1/PD-1L axis is
hyper-activated by cancer cells to evade the immune surveillance [5]. Several therapeutic Abs that
inhibit either PD-1 or PD-1L have been tested in clinical trials and some of them (namely, pembrolizumab,
nivolumab, atezolizumab, avelumab, durvalumab, and cemiplimab) are FDA-approved for different
types of cancer. However, less expensive treatments alternative to monoclonal Abs (e.g., peptides) are
continuously sought. In a first study, mirror-image phage display was employed. In this protocol,
a D-version (mirror image) of a natural target protein (composed of L aa) is produced by chemical
synthesis and used to screen L-peptide libraries displayed on phages. D-versions of the selected
L-peptides are then synthesized, which, by symmetry, are expected to bind to the target protein.
Such D-peptides usually exhibit better stability in vivo than their L-counterparts so they are preferred
for some applications. A D-version of PD-L1 IgV domain was used as a bait for a 12-mer library
produced on fd phages. The two most represented selected motifs, PPA-1 (NYSKPTDRQYHF) and
PPA-2 (KHAHHTHNLRLP) were synthesized as D-peptides and their specificity was confirmed
by surface plasmon resonance. In competition experiments, both peptides blocked PD-1/PD-L1
interaction at the cellular level, as evaluated by flow cytometry. In vivo, both peritumoral and
intraperitoneal injection of DPPA-1 inhibited the growth of syngeneic CT26 colon carcinomas in BALB/c
mice. Biodistribution analysis showed efficient delivery of the peptide, with specific accumulation in
the tumor mass and background uptake by the liver, kidney, stomach, and lungs [117]. A bacterial
surface display library was used by Li and colleagues to identify PD-L1-binding peptides, obtaining
several clones with the consensus sequence CWCWR. A focused library with the format x5CWCWRx5
was then prepared and screened. The best candidate, TPP-1 (SGQYASYHCWCWRDPGRSGGSK),
(i) bound to human PD-L1 specifically and with high affinity, (ii) reversed PD-L1-mediated inhibition
of T lymphocyte activation in terms of proliferation and IFN-γ release, and (iii) delayed tumor growth
in a xenograft model, with effects comparable to the FDA-approved Ab durvalumab [118]. In another
work, a truncated version of PD-1 bearing the mutation C93S was displayed as a fusion with the
pIII of fd phage and used as a template to construct a library by site-specific mutagenesis of 24 aa.
The deriving phage-displayed library was panned on human PD-L1-biotin bound to streptavidin beads,
leading to the isolation of PD-1 variant L5B7 (VNYMSNQTKAPPGLSAILPYIQIE) with 3000-fold
affinity increase as evaluated by in vitro binding assays on recombinant PD-L1. PBMCs stimulated
with anti-CD3 and anti-CD28 agonist Abs were used as a T-lymphocyte activation model to evaluate
the efficacy of L5B7. In these assays, L5B7 increased both PBMC proliferation and IFN-γ release by an
extent comparable to soluble human PD-1 and anti-PD-1 Ab [119]. A couple of analogous reports were
presented at the 2019 meeting of the American Association for Cancer Research (AACR). The first one
describes peptide CLP002 as a specific ligand of PD-L1 with promising activity in vitro and in vivo in
CT26 tumor-bearing mice [120]. The second one (by Avacta Life Sciences, Ltd.) describes Affimer®
biotherapeutic antagonists—monomeric scaffold proteins based on the human protease inhibitor Stefin
A—to human and mouse PD-L1, again with encouraging preclinical activity [121].
Finally, in a recent work, Son and colleagues designed a phage-displayed library based on a
small-sized non-Ab scaffold, termed “repebody”, to identify ligands of human PD-1. A clone with
high affinity (r_A1) was selected and further maturated up to a Kd = 17 nM by modular evolution.
The deriving molecule (r_G9) was validated both in vitro (specific binding in competition assays and
flow cytometry, restoration of T lymphocyte activity) and in vivo (pharmacokinetics and antitumor
effect in mice xenografted with NCI-H292 human lung cancer cells) with positive results [122].
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4.3. Modulating the Activity of Immune Cells
4.3.1. Inducing Immune Responses by Targeting APCs and T Lymphocytes
A few reports have been published that describe phage display-selected peptide ligands of
molecules expressed by specific immune cell lineages. One such molecule is CD11c/CD18 (integrinαXβ2),
which is present exclusively on the surface of APCs, particularly monocytes and dendritic cells. In a first
study, a cyclic 10-mer (CL10) and a linear 9-mer (LL9) libraries were panned on CD11c/CD18 purified
from the spleen of a patient with hairy cell leukemia. The circular peptide motif CGRWSGWPADLC
was isolated as a ligand of CD11c/CD18 on monocytes, as established by in vitro binding assays, surface
plasmon resonance, and flow cytometry. This motif shares similarity with both the linear GNWTWP
epitope in domain D5 and the phase-shifted PEDNGRSFS epitope in domain D4 of Intercellular
Adhesion Molecule 1 (ICAM-1), the molecular partner of CD11c/CD18. Binding assays with deletion
mutants of ICAM-1 mapped the binding region to domain D4 [123]. In a successive study, this same
peptide (p30) plus two additional peptides derived from the CD11c/CD18-interacting portion of ICAM-4
(p17 and p18) were individually fused to a 12x histidine tag and crosslinked to stealth liposomes. Specific
binding to human monocyte-derived dendritic cells, the murine dendritic cell line DC2.4, and CD11c+
murine splenocytes was validated by flow cytometry. In vivo, tracer-embedding liposomes, engrafted
with the CD11c/CD18-binding peptides and administered intravenously, accumulated specifically in
CD11c+ splenocytes. The potential of CD11c-targeting liposomes to induce an immune response was
first evaluated in healthy C57BL/6 mice, observing (i) an increase in splenocyte proliferation (30- to
59-fold, depending on the displayed peptide), (ii) specific expansion of IFN-γ-producing CD8+ T
lymphocytes, and (iii) production of high-titer IgG1. Tumor cell-derived plasma membrane vesicles
(PMV) grafted with the CD11c-targeting peptides (p18-PMV and p30-PMV) were evaluated for their
efficacy as prophylactic and/or therapeutic vaccine in mice bearing subcutaneous syngeneic melanoma
B16-OVA cells. In both settings, treatment with pCD11c-PMV led to a marked reduction in the number
of lung metastases and regression of the primary tumor, which was complete in some cases [124].
Another marker highly expressed on the surface of dendritic cells is the C-type lectin Clec9a,
a protein involved in antigen uptake and induction of humoral immunity. A 12-mer phage displayed
library was used to screen murine Clec9a C-type lectin-like domain fragment, retrieving four motifs,
one of which (peptide WH of sequence WPRFHSSVFHTH) was further validated by in silico and
in vitro studies. An OVA257–264-conjugated version of WH increased IFN-γ secretion by Clec9a+
dendritic cells and promoted antigen-specific CTL induction, measured as increased mRNA levels
of both IFN-γ and cytotoxicity markers (perforin and granzyme B). In vivo, OVA257–264-WH was
evaluated as a potential vaccine in the B16-OVA lung metastasis model, observing a marked decrease
in the numbers of lung foci, paralleled by induction of IFN-γ and cytotoxicity markers in splenocytes,
at a higher extent compared with OVA alone [125]. Both CD11c/CD18 and Clec9a have a functional
role in the first phases of the immune response, namely antigen presenting and T-lymphocyte priming,
therefore the targeting peptides may have a direct effect in addition to function as a vaccine.
Phage display-derived peptides have also found applications in later stages of the immune
response involving the action of T lymphocytes. In a pioneering work, Kraft and colleagues panned
a 12-mer library on recombinant αvβ6 integrin expressed as a transmembrane truncated soluble
receptor, retrieving the RGD motif in 51% of the clones and the DLxxLx motif in 27%, the latter
proving to be highly specific for αvβ6 [126]. From the clones selected in this study, the peptide
motif RTDLDSLRTYTL (Bpep) was exploited in a successive work to serve as a Chimeric Antigen
Receptor (CAR) targeting domain. Primary human T lymphocytes were genetically modified to
express the Bpep-CAR, consisting of the αvβ6-binding peptide followed by a triple glycine linker,
an IgG4 hinge region, the CD4 transmembrane domain, and the cytoplasmic signaling domain of
CD3-ξ. In vitro, the Bpep-CAR-exposing lymphocytes recognized and killed the human ovarian cancer
cell line OVCAR-3 and two primary ovarian tumor lines (RSN001 and RSN002), all positive for αvβ6
integrin. Upon engagement with αvβ6 integrin, Bpep-CAR-expressing T lymphocytes were activated
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to release high levels of IFN-γ [127]. Since many tumor-targeting peptides have been identified by
phage display, it is expected to see more applications in the field of CAR T cells in the near future.
Another subpopulation of effector cells, T lymphocytes bearing the γδTCR, show promise
in immunotherapy because of their potent cytotoxicity toward various types of tumor cells.
A panel of complementary determining regions (CDR3δ) derived from ovarian epithelial carcinoma
infiltrating γδT lymphocytes was screened with a 12-mer phage library obtaining seven putative
epitopes (EP1, WPHNWWPHFKVK; EP2, PLLPMHPMKVSH; EP3, KPPTQKRRRQTM; EP4,
RPRTRLHTHRNR; EP5, YPWHWWHSVSPW; EP6, FHWSWYTPSRPS; and EP7, WHHPWWYPRPGV).
The following tandem epitopes were constructed as GTS fusion proteins: EPt4 (EP1-EP5-EP6-EP7),
EPt7 (EP1-EP2-EP3-EP4-EP5-EP6-EP7) and EPt8 (EP1-EP5-EP6-EP7-EP1-EP5-EP6-EP7). In vitro,
the tandem peptides (i) activated γδT lymphocytes by inducing proliferation and release of IL-2,
IFN-γ, TNF-α, FasL, and granzyme B and (ii) triggered tumor cell cytotoxicity, being GST-EPt7 the
most active. In BALB/c nude mice carrying human ovarian cancer SKOV3 cells, co-administration
of GST-EPt7-preactivated γδT lymphocytes and IL-2 resulted in smaller tumors and extended
survival [128].
4.3.2. Reducing Immunosuppression by Targeting Tumor-Associated Macrophages and Treg Cells
Other immune cells such as tumor-associated macrophages (TAMs) impact on cancer growth by
influencing the adaptive immune responses. Depending on different exogenous stimuli, TAMs are
found in two polarization states with opposite functions: IFN-γ and lipopolysaccharide (LPS)
trigger a proinflammatory phenotype (M1-like), while IL-4 and IL-13 induce an anti-inflammatory
phenotype (M2-like) characterized by poor antigen presentation, stimulation of angiogenesis, and tissue
remodeling. The number of infiltrating M2 TAMs correlates with tumor progression, drug resistance,
and poor survival. In this case, it is desirable to inhibit their activity and/or selectively deplete
them from the tumor microenvironment. Cieslewicz and colleagues designed a subtractive phage
panning strategy using in vitro-activated subpopulations of M1 and M2 macrophages. An M2-specific
peptide, M2pep (YEQDPWGVKWWY), was isolated and validated against mixed populations of
primary cells. M2pep was fused to the pro-apoptotic peptidomimetic D(KLAKLAK)2 (KLA) [129],
and the efficacy of the deriving conjugate was evaluated in vitro and in vivo. Following intravenous
administration of M2pep-KLA, BALB/c mice bearing the CT26 model showed prolonged survival rates
and slower-growing tumors with reduced infiltration of M2-like TAMs [130].
Tregs are immunosuppressive cells whose function is often exploited by tumor cells to evade
the immune responses. Few approaches have been designed to inactivate Tregs from the tumor
microenvironment, but with diverse outcomes due to an overall lack of specificity. Moreover, Tregs do
not expose cell-surface markers—the most specific marker is Foxp3, an intracellular transcription
factor—so they are quite difficult to target. By screening a phage-displayed library, Casares and
colleagues identified a 15-mer synthetic peptide (P60, of sequence RDFQSFRKMWPFFAM) [131],
which was able to enter the cell, bind to Foxp3 and inhibit its nuclear translocation. As the peptide can
penetrate any cell in the body, the amount required to exhibit an anti-tumoral effect would be high,
limiting the clinical feasibility of this approach. Therefore, P60 was fused to an aptamer to obtain the
conjugate CD28Apt-P60 with double targeting properties (CD28-expressing cells and Fox3). In vitro,
CD28Apt-P60 inhibited Treg activity more efficiently than the unconjugated peptide. In vivo, systemic
administration of CD28Apt-P60 resulted in improved efficacy of an OVA-based vaccine and reduction
of tumor burden in the CT26 model in a prophylactic setting [132].
4.4. Conclusions for this Section
Phage display-selected peptides can be exploited as modulators of immune cell activity in terms
of stimulation of effector cells (APCs, lymphocytes) and/or inhibition of suppressor cells (TAMs, Tregs).
Because these approaches have demonstrated good efficacy and specificity coupled with low or absent
toxicity, they may offer a good alternative to Ab-based immunotherapy. The growing evidence available
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in the literature supports the feasibility of these applications, which are likely to be taken to clinical
studies soon. A list of the phage display-derived peptide modulators of the immune system described
in this section, with reference to the target molecule/cell type and specific effect, is provided in Table 3.
Table 3. Phage display-derived peptides as direct nanomodulators of the immune response.
Target Effect Peptide Motif Reference
IgM λ receptor Activation ofB-lymphoma cells
KP–xRV
-W–WxR
Y–EDLRRR
–PVDHGL
[114,115]
Melanin
Reversal of
melanin-induced
immune response
HTTHHRN
TTHQFPF
NPNWGPR
[116]
PD-L1 and PD-1
Competitive inhibition of
PD-1/PD-L1 binding
NYSKPTDRQYHFKHAHHTHNLRLP [117]
SGQYASYHCWCWRDPGRSGGSK [118]
VNYMSNQTKAPPGLSAILPYIQIE [119]
CLP002 [120]
Affimer® antagonists [121]
r_G9 repeabdy [122]
CD11c/CD18 integrin
αXβ2
Targeting of APCs and
induction of CTLs
CGRWSGWPADLC [123,124]
Clec9a WPRFHSSVFHTH [125]
αvβ6 integrin CAR RTDLDSLRTYTL [127]
CDR3δ Activation of γδT cells
WPHNWWPHFKVK
PLLPMHPMKVSH
KPPTQKRRRQTM
RPRTRLHTHRNR
YPWHWWHSVSPW
FHWSWYTPSRPS
WHHPWWYPRPGV
[128]
M2 TAMs Reduction of infiltrationby M2 TAMs YEQDPWGVKWWY [130]
Foxp3 Inhibition of Treg activity RDFQSFRKMWPFFAM [131,132]
5. Final Remarks
Phage display is a powerful nanotechnology with broad applications. In the rising field of tumor
immunology, phage display-selected peptides can be included in a therapeutic regimen as mimotopes
(prophylactic and/or therapeutic vaccines) or used as small-molecule effectors (activators or inhibitors
of immune cells, effectors of immune checkpoint molecules). In addition, phages themselves are
suitable carriers for peptide and protein vaccines due to their immunogenicity coupled with low
toxicity, although more studies are needed to fully clarify their interaction with the mammalian
host. As yet, there are no commercial phage-derived medicines for cancer immunotherapy [133,134].
This limitation arises primarily from the difficulties associated with peptide stability and delivery,
phage immunogenicity, and from the challenges posed by the diversity of human immunogenetics [84].
Nevertheless, such nanotechnological systems, supported by state-of-the art instrumentation and
bioinformatics, have the potential to represent innovative and efficient tools for personalized application
in the near future.
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